Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS12 | P56730 | 1/20 | 0.54 |
| ▸ | CHEK2 | O96017 | 4/20 | 0.53 |
| ▸ | MMP2 | P08253 | 5/20 | 0.50 |
| ▸ | MMP9 | P14780 | 5/20 | 0.50 |
| ▸ | MMP8 | P22894 | 5/20 | 0.50 |
| ▸ | MMP13 | P45452 | 4/20 | 0.50 |
| ▸ | NPBWR1 | P48145 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.49 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.49 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14381437 | 0.94 | MMP2 (0.61) | PRSS12CHEK2MMP2MMP9MMP8 | |
| SCHEMBL14381482 | 0.94 | MMP2 (0.61) | PRSS12CHEK2MMP2MMP9MMP8 | |
| SCHEMBL14381457 | 0.93 | MMP2 (0.61) | PRSS12CHEK2MMP2MMP9MMP8 | |
| SCHEMBL14381759 | 0.90 | PRSS12 (0.64) | PRSS12CHEK2NPC1RAB9ALMNA | |
| SCHEMBL14381787 | 0.90 | PRSS12 (0.64) | PRSS12CHEK2NPC1RAB9ALMNA | |
| SCHEMBL14381814 | 0.90 | PRSS12 (0.64) | PRSS12CHEK2NPC1RAB9ALMNA | |
| SCHEMBL14381762 | 0.90 | PRSS12 (0.64) | PRSS12CHEK2NPC1RAB9ALMNA | |
| SCHEMBL14381760 | 0.88 | PRSS12 (0.62) | PRSS12CHEK2NPC1RAB9ALMNA | |
| SCHEMBL14381772 | 0.86 | PRSS12 (0.60) | PRSS12CHEK2RAB9ARIPK1MEN1 | |
| SCHEMBL5223779 | 0.85 | PRSS12 (0.58) | PRSS12CHEK2MAPTRAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7282518-B2 | Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation | AVANIR PHARMACEUTICALS (US) | 2007-10-16 | — | — | US | disclosed |
| US-20070202133-A1 | BENZIMIDAZOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION | SIRCAR JAGADISH C | 2007-08-30 | — | — | US | disclosed |
| EP-1368028-B1 | BENZIMIDAZOLE COMPOUNDS FOR MODULATING IGE AND INHIBITING CELLULAR PROLIFERATION | AVANIR PHARMACEUTICALS (US) | 2007-08-15 | — | — | EP | disclosed |
| US-20040214821-A1 | Useful in the treatment of allergy and/or asthma or any diseases where Immunoglobulin E (IgE) is pathogenic; anticancer agents | SIRCAR JAGADISH C (US) | 2004-10-28 | — | — | US | disclosed |
| US-6759425-B2 | USEFUL IN THE TREATMENT OF ALLERGY AND/OR ASTHMA OR ANY DISEASES WHERE IGE IS PATHOGENIC; ALSO ARE USEFUL AS ANTICANCER AGENTS. | AVANIR PHARMACEUTICALS | 2004-07-06 | — | — | US | disclosed |
| EP-1368028-A1 | BENZIMIDAZOLE COMPOUNDS FOR MODULATING IGE AND INHIBITING CELLULAR PROLIFERATION | AVANIR PHARMACEUTICALS (US) | 2003-12-10 | — | — | EP | disclosed |
| WO-2002072090-A1 | BENZIMIDAZOLE COMPOUNDS FOR MODULATING IGE AND INHIBITING CELLULAR PROLIFERATION | AVANIR PHARMACEUTICALS (US) | 2002-09-19 | — | — | WO | disclosed |
| US-20020132808-A1 | Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation | AVANIR PHARMACEUTICALS | 2002-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070202133-A1 | BENZIMIDAZOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION | MKI67, CMA1, CCNI | PRSS12 3287/4885CHEK2 2484/4885MMP2 760/4885 |
| US-20040214821-A1 | Useful in the treatment of allergy and/or asthma or any diseases where Immunoglobulin E (IgE) is pathogenic; anticancer agents | FCER2, CMA1, FCGR1A | PRSS12 3362/4885CHEK2 3296/4885MMP2 532/4885 |
| US-20020132808-A1 | Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation | MKI67, CMA1, CCNI | PRSS12 3287/4885CHEK2 2484/4885MMP2 760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.